Tessera Defense and Homeland Security Inc. (formerly BiomX Inc.) has 18 Schedule 13D or 13G filings on record since 2025-08-05. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Reuven Yeganeh | 19.99% | 381,422 | SCHEDULE 13D, 2026-01-26 | 2025-12-26 |
| Nantahala Capital Management, LLC | 7.13% | 730,551 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Mayers Ventures LLC | 4.86% | 130,000 | SCHEDULE 13D, 2026-09-17 | 2026-09-16 |
| James E. Flynn | 4.7% | 533,370 | SCHEDULE 13D/A, 2026-06-16 | 2026-06-12 |
| T3 Defense Inc. | 3.87% | 156,796 | SCHEDULE 13D/A, 2026-09-15 | 2026-09-15 |
| Alyeska Investment Group, L.P. | 2.5% | 38,176 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Cystic Fibrosis Foundation | 1.5% | 174,276 | SCHEDULE 13G/A, 2026-08-20 | 2026-06-30 |
| Rodney Hodges | 0.7% | 82,618 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Orin Hirschman | 0.1% | 38,175 | SCHEDULE 13G/A, 2026-01-29 | 2025-12-31 |
| Morgan Stanley | 0% | 0 | SCHEDULE 13G/A, 2025-08-07 | 2025-07-31 |
Purpose of Transaction (Item 4)
Reuven Yeganeh
The Pyu Pyu acquired the securities described in this Schedule 13D pursuant to various transactions and agreements with the Issuer, including without limitation those discussed in Item 3 of this Schedule 13D, which are incorporated herein by reference. The Reporting Persons intend to review its investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for shares of Common Stock of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of shares of Common Stock of the Issuer or disposal of some or all of the shares of Common Stock of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions. Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-26; the filing has the rest
Mayers Ventures LLC
The Reporting Persons acquired the shares for investment purposes, and have the right to an additional 65,000 shares as described above. The Reporting Persons may, from time to time, acquire additional shares of Common Stock in the open market, in privately negotiated transactions, or otherwise, or may dispose of all or a portion of the shares of Common Stock held by them, subject to applicable securities law restrictions, including any lock-up or registration requirements. The Reporting Persons may also engage in discussions with the Issuer's management, board of directors, or other stockholders regarding the Issuer's business, management, operations, strategy, or governance. Any such actions will depend upon a variety of factors, including the price and availability of the Common Stock, general market conditions, and other factors deemed relevant by the Reporting Persons. Except as described herein, the Reporting Persons do not currently have any plans or proposals that would relate to or result in any of the actions enumerated in paragraphs (a) through (j) of Item 4 of Schedule 13DItem 4 of the SCHEDULE 13D filed 2026-09-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Morgan Stanley | 7.1% | SCHEDULE 13G |
| 2025-08-07 | Morgan Stanley | 0% | SCHEDULE 13G/A |
| 2026-01-26 | Reuven Yeganeh | 19.99% | SCHEDULE 13D |
| 2026-01-29 | Orin Hirschman | 0.1% | SCHEDULE 13G/A |
| 2026-02-11 | James E. Flynn | 9.99% | SCHEDULE 13D/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Alyeska Investment Group, L.P. | 2.5% | SCHEDULE 13G/A |
| 2026-04-10 | T3 Defense Inc. | 19.87% | SCHEDULE 13D |
| 2026-04-14 | T3 Defense Inc. | 20.4% | SCHEDULE 13D/A |
| 2026-04-15 | James E. Flynn | 9.99% | SCHEDULE 13D/A |
| 2026-05-14 | Rodney Hodges | 5.2% | SCHEDULE 13G/A |
| 2026-05-28 | James E. Flynn | 8.09% | SCHEDULE 13D/A |
| 2026-06-16 | James E. Flynn | 4.7% | SCHEDULE 13D/A |
| 2026-08-13 | Rodney Hodges | 0.7% | SCHEDULE 13G/A |
| 2026-08-14 | Nantahala Capital Management, LLC | 7.13% | SCHEDULE 13G/A |
| 2026-08-20 | Cystic Fibrosis Foundation | 1.5% | SCHEDULE 13G/A |
| 2026-09-15 | T3 Defense Inc. | 3.87% | SCHEDULE 13D/A |
| 2026-09-17 | Mayers Ventures LLC | 4.86% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Tessera Defense and Homeland Security Inc. (formerly BiomX Inc.). With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
